Background: Fibroadenoma is a benign solid tumor composed of stromal and epithelial components, it is the second most common tumor in breast and most common tumor in young females below 40 years. Fibrosfenosis is another cause of breast pain which is cyclical in nature and usually pain increases just before onset of menstruation and gradually reduces after menstruation. Mastalgia is another common and challenging symptoms affecting 70% of female population. Methods: Data collection was started after obtaining clearance from the institute ethical committee. After the inclusion criteria’s were met those patient diagnosed of fibroadenoma or mastalgia using triple assessment, were started with tab ormeloxifene 30 mg twice a week for a duration of three months. Patient was followed up at regular intervals for three months with regression of tumour size using ultrasound and visual analog score for mastalgia. Results: The study included 100 female patients, 60 of whom had fibroadenoma with or without mastalgia, and 40 of whom had mastalgia alone. Of the 60 patients with fibroadenoma, 43 had fibroadenoma without mastalgia, while 17 had fibroadenoma with mastalgia. The mean age of the subjects was 29.47 years. The size of the breast lump decreased significantly over time, with the mean size being 2.14 cm on day 1 and 0.71 cm on day 90. The VAS score also decreased significantly over time, with the mean VAS score being 5.15 on day 1 and 0.19 on day 90. The data suggests that ormeloxifene treatment can be an effective option for the treatment of fibroadenoma, with a relatively high complete response rate and a low rate of adverse effects. Conclusion: Ormeloxifene is a nonsteroidal drug found to be effective in the treatment of mastalgia and partially responsive in treating fibroadenomas in a short time period of 3 months with minimal side effects. Now patients are being followed up to look for recurrence of lump, pain or to look for the increase in the size of partially reduced fibroadenomas as there is a need for further evaluation.